| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.37 M USD | -2.52 M USD | -3.60 M USD | -7.04 M USD | -4.37 M USD | -3.39 M USD | -3.87 M USD | -3.55 M USD | -2.18 M USD | -1.53 M USD | -1.48 M USD | -900000 USD |
| Depreciation & Amortization | 897000 USD | 1000 USD | 1000 USD | 1000 USD | 2000 USD | 2000 USD | 4000 USD | 6000 USD | 5000 USD | 7000 USD | 9000 USD | 9000 USD |
| Stock-Based Compensation | — | 356000 USD | 293000 USD | 354000 USD | 382000 USD | 376000 USD | 1.75 M USD | 889000 USD | 800000 USD | 508000 USD | 220000 USD | 24000 USD |
| Capital Expenditures | 60000 USD | 3000 USD | 1000 USD | 3000 USD | 3000 USD | 2000 USD | — | 8000 USD | — | 8000 USD | 1000 USD | 4000 USD |
| Cash Flow from Investing | 88000 USD | -3000 USD | -1000 USD | -3000 USD | -3000 USD | -2000 USD | — | -8000 USD | — | -8000 USD | -1000 USD | -4000 USD |
| Cash Flow from Financing | 12.79 M USD | 1000 USD | 4.22 M USD | 2.09 M USD | 4.58 M USD | 9.52 M USD | 4.32 M USD | 94000 USD | 6.44 M USD | 33000 USD | 3.00 M USD | 900000 USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -9.43 M USD | -2.52 M USD | -3.60 M USD | -7.04 M USD | -4.37 M USD | -3.39 M USD | — | -3.56 M USD | — | -1.54 M USD | -1.48 M USD | -904000 USD |
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at-home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. The company was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. The company was incorporated in 2003 and is based in Tyler, Texas.